Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > People are impatient, they sell too early.

<< Previous

Bullboard Posts

Next >>

Comment by grosdavidon May 11, 2020 11:24am

105 Views

Post# 31012023

RE:People are impatient, they sell too early.

Agree, don't worry it will always bite back.

The greed makes you think you can make money elsewhere, quicker and easier. Wrong mindset.

Don't worry, we know something is going on right now, they aren't in their offices sitting back. Things are moving and we will be updated soon.

Some just need that little NR reminding them why they are here in the first place. Don't forget what has been proven uptil now.

Don't panick.
David

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle